Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01)

The summary for the Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01): Purpose. The purpose of this FOA is to foster the development of novel pharmacological strategies for the treatment of pregnant/postpartum women with Substance Related Disorders (SRDs) and/or in utero substance exposed neonates. To that end, this FOA issued by NIDA, National Institutes of Health, will encourage applications to implement preclinical and clinical research directed towards: 1) the identification, evaluation, and development of safe and effective novel pharmacotherapies (e.g., new chemical entities or immunotherapies) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates, and/or 2) the evaluation of the safety and efficacy of FDA approved medications (e.g., medications approved for a different indication) for the treatment of pregnant/postpartum women with SRDs and/or in utero substance exposed neonates. Mechanism of Support. This FOA will use the NIH Research Project Grant (R01) mechanism and runs in parallel with a FOA of identical scientific scope, PA-09-107 that encourages applications under the Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Federal Grant Title:	Medications Development for the Treatment of Pregnant/Postpartum Women with Substance Related Disorders and/or In Utero Substance Exposed Neonates (R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PA-09-106
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	May 07, 2012
Original Application Deadline:	May 07, 2012
Posted Date:	Mar 03, 2009
Creation Date:	Mar 03, 2009
Archive Date:	Jun 07, 2012
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...